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ÖZ
Meme kanserinin fallop tüpüne metastazı oldukça nadir görülür. 
Tedavi ve prognozları farklı olduğundan primer fallop tüpü tümörü 
ile fallop tüpüne meme kanseri metastazının birbirinden ayırt 
edilmesi ve durumun cerrahiden önce patolojik olarak doğrulanması 
zordur. Biz burada 13 yıl önce meme kanseri nedeniyle sol 
modifiye radikal mastektomi hikayesi olan 46 yaşında bir kadın 
hastayı sunduk. Hasta sol adneksiyel kitle ile başvurdu. Total 
abdominal histerektomi ile birlikte bilateral salpingo-ooferektomi 
yapıldı. Immünhistokimyasal olarak tümör hücreleri sitokeratin 7 
(CK7), östrojen reseptörü (ER) ve progesteron reseptörü (PR) ile 
pozitif boyandı. Mammoglobulin (x2), P53, CK20, GCDFP-15, 
trombomodulin ve HER2 boyası negatifti. HER2 için floresan 
in situ hibridizasyon (FISH) negatifti. Hastaya tümörün hem 
morfolojik hem de immünfenotipik özellikleri nedeniyle meme 
kanserinin fallop tüpüne metastazı tanısı konulmuştur.
Anahtar kelimeler: Fallop tüp kanseri, Meme kanseri, Fallop 
tüpüne metastaz
Introduction
Breast cancer is the most common malignancy in women. 
Breast cancer usually presents as a localized disease, 
however, one to five percent of women diagnosed with 
breast cancer have metastatic disease on presentation. 
Another 30 percent of women with early-stage breast cancer 
at diagnosis would develop distant metastatic disease after 
treatment [1]. Metastatic breast cancer is unlikely to be 
cured; median survival is approximately 18 to 24 months, 
though this varies based on subtype of tumor, sites of 
metastatic involvement, and burden of metastatic disease 
[2]. The most common metastasic sites are the lung, liver, 
brain, and bone [3].
We report the development of metastasis to the fallopian 
tube in a 46 year-old woman who had prior history of breast 
carcinoma.
ABSTRACT
Breast carcinoma metastasis to the fallopian tube is extremely 
rare. Distinction between a primary fallopian tumor and metastasis 
of breast cancer is crucial since treatment and prognosis are 
different. However, it is difficult to confirm pathologically without 
surgery. Herein, we report a 46-year-old woman with a history 
of left modified radical mastectomy for breast cancer 13 years 
ago, presenting with a left adnexial mass. She underwent total 
abdominal hysterectomy with bilateral salpingo-oophorectomy. 
Pathology findings revealed cytokeratin (CK) 7, ER, and PR 
positive tumor cells. Mammoglobuline, P53, CK20, GCDFP-15 
and, thrombomoduline were negative. HER2 was also 2+. 
Fluorescence in situ hybridization (FISH) for HER2 was negative. 
Based on the morphology and immunophenotype of the tumor, 
we established the diagnosis as metastasis of breast cancer to the 
fallopian tube.
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Case Report
A 46-year-old woman presented with chest pain in April 
2015. In 2002, she was treated for invasive ductal carcinoma 
(estrogen receptor (ER) +, progesterone receptor (PR) +, 
and the human epidermal growth factor receptor 2(HER2), 
pT2N2M0) with left modified radical mastectomy, adjuvant 
chemotherapy and radiotherapy, followed by anti-hormonal 
therapy with tamoxifen for 5 years. There was no history 
of any other systemic disease. On admission, she was not 
using any medication. Thoracic computed tomography 
(CT) scan revealed left pleural effusion. Abdominopelvic 
CT demonstrated intraabdominal multiple lenfadenopathies 
and a 7×6.5 centimeter parauterine cystic mass. On (18) 
F-fluorodeoxyglucose ((18) F-FDG) positron emission 
tomography/computed tomography (PET/CT), left pleural 
effusion, multiple hypermetabolic metastatic nodules in 
the left lung, bilateral hilar and abdominal hypermetabolic 
metastatic lenfadenopathies, and a 7×7 centimeter left 
adnexal hypermetabolic mass (maximum standardized 
uptake values (SUV max): 12) were demonstrated. Serum 
CA 12-5 level was normal [26 U/ml (normal < 35 U/ml)]. 
Serum CA 15-3 level was markedly elevated [231 U/
ml (normal < 38.6 U/ml)]. In May 2015, total abdominal 
hysterectomy with bilateral salpingo-oophorectomy was 
performed. Frozen-section test revealed a 7.5×6.5×6 cm 
cystic mass on the wall of the left fallopian tube. There were 
no pathologic findings for the ovaries, endometrium, and 
the right fallopian tube. Serous fluid within the cyst was 
drained. Cyst wall thickness was 2 mm. Histopathological 
examination revealed a 2 mm malignant epithelial tumor 
on the wall of the fallopian tube (Figure 1). Tumor was 
diffusely stained with cytokeratin (CK) 7, ER, and PR 
(Figure 2). Staining for mammoglobuline, P53, CK20, 
Figure 1. The tumor is located in tubal stromal tissue under 
cuboidal ciliated tubal epithelium. It is composed of diffuse 
sheets, well defined nests, cords or as individual cells 
Figure 2a. Tumoral cells show positive immunostaining for CK 7x100 
Figure 2b. Tumoral cells show positive immunostaining for ER x100 
Figure 2c. Tumoral cells show positive immunostaining for PR x100 
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GCDFP-15 and thrombomoduline were negative. HER2 
was also 2+. Fluorescence in situ hybridization (FISH) 
for HER2 was negative. Histopathological examination 
revealed similarities between the specimens of the breast 
and the fallopian tube. The definitive histopathological 
diagnosis was consistent with metastatic breast carcinoma to 
the fallopian tube. Six cycles of docetaxel (75 mg/m2 every 
3 weeks) were planned with the diagnosis of metastatic 
breast carcinoma.
Discussion
Metastases to the fallopian tubes from non-gynecologic 
cancers are uncommon. Most common metastases to the 
fallopian tubes are from gynecologic carcinomas. The reason 
for the metastases to the fallopian tubes can be the spread 
of the breast and colorectal cancers. In a retrospective study 
including, 325 cases with metastasis to the female genital 
tract, one hundred forty-nine (45%) cases were metastatic 
from non-gynecologic cancers. Average age of the patients 
with metastases from non-gynecologic cancers was 53.1 
years. In 128 of the 149 cases (86%) the primary tumor was 
diagnosed previous to or concurrent with the discovery of 
the metastasis. In 21 cases, metastasis was the first finding, 
resulting in a search for the primary neoplasm. The study 
showed that the most common primary neoplasms were 
colorectal (37.6%) and breast cancers (34.9%). The most 
frequent metastatic sites for non-gynecologic cancers 
were the ovaries and the vagina. None of the patients with 
breast carcinomas had fallopian metastasis in this study 
[4]. In another case series of 100 non-gynecologic cancers 
metastasized to the fallopian tubes, most tumors were 
adenocarcinoma (87%), and remainder were lymphomas, 
neuroendocrine tumors, and mesotheliomas. Most common 
primary neoplasms were colon (35%), and breast cancers 
(15%). The anatomic distribution of metastases included the 
tubal mucosa (29%), submucosa (43%), muscularis propria 
(54%), serosa (76%), lymphovascular spaces (38%), 
intraluminal space (16%), and mesonephric remnants (39%). 
Thirty-five percent of the cases had an apparent tubal nodule 
or mass. Tumor involved the fimbriae in 49% of the cases, 
including 10% of cases in which the tumor was restricted to 
the fimbriae without involving the nonfimbriated portion of 
the tube [5].
In a similar case report, a 36-year-old woman had 
two successive primary cancers of the breast (left, right) 
removed surgically. At the time of the second mastectomy 
a bilateral salpingo-oophorectomy was also performed. 
Unexpectedly, breast cancer metastasis was found on the 
right fallopian tube; infiltrating cancer was also present in 
the left ovary [6].
The development of an adnexial mass in patients 
with a history of breast cancer cause therapeutic 
and diagnostic dilemmas. An accurate histological 
examination including appropriate immunohistochemical 
panel is needed to discriminate primary tubal tumors from 
metastatic lesions from the breast. ER, PR, and HER2 
receptor status have prognostic and predictive value for 
patients with metastatic breast cancer. Expression of 
these receptors may be discordant between recurrent and 
primary breast cancers, therefore a repeat biopsy may 
be needed in women with metastatic breast cancer. In a 
pooled analysis of two prospective studies, the rates of 
discordance in ER, PR, and HER2 between the primary 
and recurrent breast cancers were 13%, 31%, and 5.5%, 
respectively [7]. In another prospective observational 
study, rates of discordance for ER, PR, and HER2 were 
13%, 28%, and 3%, respectively [8]. In our case, ER, PR, 
and HER2 receptor were positive in the primary breast 
tumor but HER2 was negative while ER and PR were 
positive in metastatic breast tumor lesion.
Breast carcinoma metastasis to the fallopian tube is 
rare. Clinicians should evaluate whether the tubal lesion 
in a patient with a history of breast cancer is metastatic or 
primary, because treatments and prognosis are different. 
Patients with metastasis to the fallopian tubes should be 
treated with systemic chemotherapy.
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